Anti-cancer AI tools developer Lunit gets $61m pre-IPO funding round | AltAssets Private Equity News

Funding Rounds

▤ Summary

Lunit is working on AI-powered diagnostic tools for cancer screening, as well as biomarkers that can accurately predict and guide which patients respond to specific cancer therapy. Never miss a story – click to sign up to AltAssets’ free daily PE newsletter The company is set for an IPO on the South Korean stock market early next year. HealthQuest Capital invested $20m of the latest funding round. Firm managing partner Garheng Kong said, “At HealthQuest, we’re highly interested in AI advancement and its application to complex diagnostic procedures to improve accuracy and reduce complexity. “Lunit stands out as best-in-class for its state-of-the-art solutions (which uses a paired modality approach) across multiple products, and has significant initial commercial traction around the world.” Lunit previously closed a strategic investment of $26m from Guardant Health last July.

$ Funding

$
Amount - Total raised
□
Date - Announcement date
◎
Investors Casdin Capital, 2bCrowdFunded Digital Magazine, HealthQuest Capital Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
Medical AI Software Healthcare Software Clinical Decision Support

▦ Linked Companies

Lunit
$10M to $25M